400 related articles for article (PubMed ID: 16828940)
61. Cellular immune responses to HPV-18, -31, and -53 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles.
Pinto LA; Viscidi R; Harro CD; Kemp TJ; García-Piñeres AJ; Trivett M; Demuth F; Lowy DR; Schiller JT; Berzofsky JA; Hildesheim A
Virology; 2006 Sep; 353(2):451-62. PubMed ID: 16863657
[TBL] [Abstract][Full Text] [Related]
62. Oral immunization with different assembly forms of the HPV 16 major capsid protein L1 induces neutralizing antibodies and cytotoxic T-lymphocytes.
Thönes N; Müller M
Virology; 2007 Dec; 369(2):375-88. PubMed ID: 17822733
[TBL] [Abstract][Full Text] [Related]
63. Development of a highly thermostable, adjuvanted human papillomavirus vaccine.
Hassett KJ; Meinerz NM; Semmelmann F; Cousins MC; Garcea RL; Randolph TW
Eur J Pharm Biopharm; 2015 Aug; 94():220-8. PubMed ID: 25998700
[TBL] [Abstract][Full Text] [Related]
64. Plasmid encoding papillomavirus Type 16 (HPV16) DNA constructed with codon optimization improved the immunogenicity against HPV infection.
Cheung YK; Cheng SC; Sin FW; Xie Y
Vaccine; 2004 Dec; 23(5):629-38. PubMed ID: 15542183
[TBL] [Abstract][Full Text] [Related]
65. Efficiency of HPV 16 L1/E7 DNA immunization: influence of cellular localization and capsid assembly.
Kuck D; Leder C; Kern A; Müller M; Piuko K; Gissmann L; Kleinschmidt JA
Vaccine; 2006 Apr; 24(15):2952-65. PubMed ID: 16414157
[TBL] [Abstract][Full Text] [Related]
66. A Novel Human Papillomavirus 16 L1 Pentamer-Loaded Hybrid Particles Vaccine System: Influence of Size on Immune Responses.
Jia C; Yang T; Liu Y; Zhu A; Yin F; Wang Y; Xu L; Wang Y; Yan M; Cai Q; Liang X; Ju R; Chen J; Wang L
ACS Appl Mater Interfaces; 2018 Oct; 10(42):35745-35759. PubMed ID: 30360122
[TBL] [Abstract][Full Text] [Related]
67. Human papillomavirus type 11 neutralization in the athymic mouse xenograft system: correlation with virus-like particle IgG concentration.
Bryan JT; Jansen KU; Lowe RS; Fife KH; McClowry T; Glass D; Brown DR
J Med Virol; 1997 Nov; 53(3):185-8. PubMed ID: 9365880
[TBL] [Abstract][Full Text] [Related]
68. Papillomavirus-like particles for serology and vaccine development.
Kirnbauer R
Intervirology; 1996; 39(1-2):54-61. PubMed ID: 8957670
[TBL] [Abstract][Full Text] [Related]
69. Effect of preexisting neutralizing antibodies on the anti-tumor immune response induced by chimeric human papillomavirus virus-like particle vaccines.
Da Silva DM; Pastrana DV; Schiller JT; Kast WM
Virology; 2001 Nov; 290(2):350-60. PubMed ID: 11883199
[TBL] [Abstract][Full Text] [Related]
70. Production of human papillomavirus type 33 L1 major capsid protein and virus-like particles from Bacillus subtilis to develop a prophylactic vaccine against cervical cancer.
Baek JO; Seo JW; Kwon O; Park SM; Kim CH; Kim IH
Enzyme Microb Technol; 2012 Mar; 50(3):173-80. PubMed ID: 22305172
[TBL] [Abstract][Full Text] [Related]
71. Vaccination of healthy volunteers with human papillomavirus type 16 L2E7E6 fusion protein induces serum antibody that neutralizes across papillomavirus species.
Gambhira R; Gravitt PE; Bossis I; Stern PL; Viscidi RP; Roden RB
Cancer Res; 2006 Dec; 66(23):11120-4. PubMed ID: 17145854
[TBL] [Abstract][Full Text] [Related]
72. Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region.
Kondo K; Ishii Y; Ochi H; Matsumoto T; Yoshikawa H; Kanda T
Virology; 2007 Feb; 358(2):266-72. PubMed ID: 17010405
[TBL] [Abstract][Full Text] [Related]
73. Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers.
Vandepapelière P; Horsmans Y; Moris P; Van Mechelen M; Janssens M; Koutsoukos M; Van Belle P; Clement F; Hanon E; Wettendorff M; Garçon N; Leroux-Roels G
Vaccine; 2008 Mar; 26(10):1375-86. PubMed ID: 18272264
[TBL] [Abstract][Full Text] [Related]
74. Non-clinical safety assessment of single and repeated intramuscular administration of a human papillomavirus-16/18 vaccine in rabbits and rats.
Segal L; Morelle D; Kaaber K; Destexhe E; Garçon N
J Appl Toxicol; 2015 Dec; 35(12):1577-85. PubMed ID: 25752809
[TBL] [Abstract][Full Text] [Related]
75. Papillomavirus-like particle based vaccines: cervical cancer and beyond.
Schiller JT; Lowy DR
Expert Opin Biol Ther; 2001 Jul; 1(4):571-81. PubMed ID: 11727495
[TBL] [Abstract][Full Text] [Related]
76. Nasal immunization of mice with human papillomavirus type 16 virus-like particles elicits neutralizing antibodies in mucosal secretions.
Balmelli C; Roden R; Potts A; Schiller J; De Grandi P; Nardelli-Haefliger D
J Virol; 1998 Oct; 72(10):8220-9. PubMed ID: 9733865
[TBL] [Abstract][Full Text] [Related]
77. Intranasal vaccination with recombinant adeno-associated virus type 5 against human papillomavirus type 16 L1.
Kuck D; Lau T; Leuchs B; Kern A; Müller M; Gissmann L; Kleinschmidt JA
J Virol; 2006 Mar; 80(6):2621-30. PubMed ID: 16501072
[TBL] [Abstract][Full Text] [Related]
78. Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial.
Safaeian M; Porras C; Pan Y; Kreimer A; Schiller JT; Gonzalez P; Lowy DR; Wacholder S; Schiffman M; Rodriguez AC; Herrero R; Kemp T; Shelton G; Quint W; van Doorn LJ; Hildesheim A; Pinto LA;
Cancer Prev Res (Phila); 2013 Nov; 6(11):1242-50. PubMed ID: 24189371
[TBL] [Abstract][Full Text] [Related]
79. Purification and immunogenicity study of human papillomavirus type 16 L1 protein in Saccharomyces cerevisiae.
Kim SN; Jeong HS; Park SN; Kim HJ
J Virol Methods; 2007 Jan; 139(1):24-30. PubMed ID: 17034867
[TBL] [Abstract][Full Text] [Related]
80. Trachea, lung, and tracheobronchial lymph nodes are the major sites where antigen-presenting cells are detected after nasal vaccination of mice with human papillomavirus type 16 virus-like particles.
Balmelli C; Demotz S; Acha-Orbea H; De Grandi P; Nardelli-Haefliger D
J Virol; 2002 Dec; 76(24):12596-602. PubMed ID: 12438585
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
